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Abstract Erucylphosphohomocholine (ErPC3, Erufo-
sine
TM) was reported previously to induce apoptosis in
otherwise highly apoptosis-resistant malignant glioma cell
lines while sparing their non-tumorigenic counterparts. We
also previously found that the mitochondrial 18 kDa
Translocator Protein (TSPO) is required for apoptosis
induction by ErPC3. These previous studies also suggested
involvement of reactive oxygen species (ROS). In the
present study we further investigated the potential
involvement of ROS generation, the participation of the
mitochondrial respiration chain, and the role of the mito-
chondrial FOF1-ATP(synth)ase in the pro-apoptotic effects
of ErPC3 on U87MG and U118MG human glioblastoma
cell lines. For this purpose, cells were treated with the ROS
chelator butylated hydroxyanisole (BHA), the mitochon-
drial respiration chain inhibitors rotenone, antimycin A,
myxothiazol, and the uncoupler CCCP. Also oligomycin
and piceatannol were studied as inhibitors of the FO and
F1 subunits of the mitochondrial FOF1-ATP(synth)ase,
respectively. BHA was able to attenuate apoptosis
induction by ErPC3, including mitochondrial ROS gener-
ation as determined with cardiolipin oxidation, as well as
collapse of the mitochondrial membrane potential (Dwm).
Similarly, we found that oligomycin attenuated apoptosis
and collapse of the Dwm, normally induced by ErPC3,
including the accompanying reductions in cellular ATP
levels. Other inhibitors of the mitochondrial respiration
chain, as well as piceatannol, did not show such effects.
Consequently, our ﬁndings strongly point to a role for the
FO subunit of the mitochondrial FOF1-ATP(synth)ase in
ErPC3-induced apoptosis and dissipation of Dwm as well as
ROS generation by ErPC3 and TSPO.
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Introduction
Glioblastomas are the most common brain tumors. They
present an unfavorable prognosis due to their aggressive-
ness and likelihood of recurrence [1]. Thus, the develop-
ment of novel anti-glioblastoma treatments is mandatory,
including an understanding of the underlying mechanisms
of potential new treatments. Alkylphosphocholines (APC)
comprise a class of anticancer agents targeting plasma
membranes [2, 3]. Previously, we discovered that the APC
derivatives erucylphosphocholine (ErPC) and its congener
erucylphosphohomocholine (ErPC3, Erufosine
TM) induce
apoptosis in otherwise highly apoptosis-resistant malignant
glioma cell lines while sparing their non-tumorigenic
counterparts [4–6]. We also found that the mitochondrial
18 kDa Translocator Protein (TSPO) is required for apop-
tosis induction by ErPC3 [7–9]. In animal experiments,
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DOI 10.1007/s10495-010-0460-5ErPC was shown to cross the blood–brain barrier after
repeated intravenous injections. Hence, it constitutes a
promising therapeutic candidate for brain tumors, including
glioblastoma [10] and currently is undergoing a clinical
phase I trial. Furthermore, we analyzed the APC-induced
cell death process and found that ErPC as well as ErPC3
promote tumor cell apoptosis independent of p53 function
and death receptor/death ligand interactions [6, 11].
We recently investigated the mechanisms by which
ErPC and ErPC3 induce cell death. Mitochondria, as well
as Apaf-1 and caspase-3, play major roles in ErPC- and
ErPC3-induced apoptosis [7, 12, 13]. ErPC3 treatment was
also found to result in mitochondrial membrane depolar-
ization and cytochrome c release in intact glioma cells [7].
Indeed, we were able to show that ErPC3 acts directly on
mitochondria. In particular, ErPC3 induced swelling of
isolated rat liver mitochondria and decreased ATP syn-
thesis in a concentration-dependent manner via permeabi-
lization of the inner mitochondrial membrane [13]. Since
ErPC3 displays direct toxic effects on mitochondria, we
concluded that ErPC3 (and its congener ErPC) target these
organelles. In support of this statement, cyclosporin A
(CsA), an inhibitor of the mitochondrial permeability
transition pore (MPTP) complex, signiﬁcantly reduced
ErPC3-induced apoptotic responses (7,13). Moreover,
using genetic manipulation of a rat glioma cell line (C6) to
induce knockdown of the 18 kDa TSPO, we demonstrated
that ErPC and ErPC3 indeed activate the mitochondrial
apoptotic pathway via the TSPO [9]. The TSPO, also
known as the peripheral-type benzodiazepine receptor
(PBR), can be found in the outer membrane of mitochon-
dria in close association with the voltage-dependent anion
channel, VDAC, and the adenosine nucleotide transporter
(ANT) [14–16]. It was further found that TSPO activation
by ErPC3 resulted in reactive oxygen species (ROS) gen-
eration leading to oxidation of cardiolipins at mitochon-
drial levels [8]. This mitochondrial ROS generation causes
activation of the MPTP and consequently dissipation of the
mitochondrial membrane potential, release of cytochrome
c, and subsequent activation of the mitochondrial apoptosis
cascade, including caspase-9 and -3 activation, and DNA
fragmentation [7, 8, 17, 18]. Thus, ErPC3 appears to be
able to activate the mitochondrial apoptosis pathway,
apparently by ROS generation as a consequence of TSPO
activation.
Mitochondria exert a dual function in the cell. On the
one hand, these organelles play a central role in deter-
mining the ‘‘point-of-no-return’’ in the apoptotic process
and on the other hand are pivotal for cellular bioenergetics
[19]. Mitochondrial oxidative phosphorylation plays a key
role in energy production, the generation of free radicals,
and apoptosis [20]. However, despite extensive study the
requirement of oxidative phosphorylation for the efﬁcient
execution of cell death is still incompletely understood and
controversial. For example, it was shown that q
o cells
devoid of mitochondrial DNA, which lack a functional
electron transport chain and are incapable of generating
ATP from mitochondria, undergo apoptosis as efﬁciently
as their parental cells [21–23]. Other authors demonstrated
the opposite, i.e. other cells devoid of mitochondrial DNA
(such as SK-Hep1 cells or C2C12 myocytes) are resistant
to apoptosis [24–26]. Similarly, oligomycin, a speciﬁc
inhibitor of the mitochondrial FOF1-ATP(synth)ase
(thereby an inhibitor of the mitochondrial electron trans-
port chain and ATP generation), showed pro-apoptotic
effects in several studies [27–29] but also anti-apoptotic
effects have been reported in other studies [30–32]. Inter-
estingly, down-regulation of the catalytic subunit (F1)o f
the mitochondrial FOF1-ATP(synth)ase is a hallmark of a
variety of different human tumors, including breast, liver
and lung tumors [33]. Thus, studies elucidating the role of
the FOF1-ATP(synth)ase in carcinogenesis are needed.
The aim of this study was to further investigate the
involvement of ROS generation in ErPC3-mediated apop-
tosis and to characterize the participation of the mitochon-
drial respiration chain and the mitochondrial FOF1-ATP
(synth)ase in the execution of ErPC3-induced cell death.
Butylated hydroxyanisole (BHA) was one ROS scavenger
used in this study in combination with assays of cardiolipin
oxidation to determine ROS generation by ErPC3. To
determine involvement of the mitochondrial respiration
chain, we used the mitochondrial respiration chain inhibi-
tors rotenone, antimycin A, myxothiazol, the uncoupler
CCCP, and oligomycin as an inhibitor of the FO subunit of
the mitochondrial FOF1-ATP(synth)ase, as well as picea-
tannol, an inhibitor of the F1 subunit of this enzyme. The
results obtained suggest a role for the FO subunit of the
mitochondrial FOF1-ATP(synth)ase in ErPC3-induced
apoptosis, dissipation of the mitochondrial membrane
potential (DWm), the generation of ROS, and ATP deple-
tion. Parts of this study have been presented in abstract
form [34–36].
Materials and methods
Cell culture
The human glioblastoma cell lines U87MG and U118MG
were generously provided by Prof. G. Bernhardt, Univer-
sity of Regensburg, Germany. Cells were cultured at 37C
in an atmosphere of 5% CO2 and 90% relative humidity, as
described previously [7]. Brieﬂy, U87MG cells were
maintained in EMEM and U118MG cells in DMEM sup-
plemented with 10% (U87MG) or 5% (U118MG) heat-
inactivated fetal bovine serum (FBS), 100 U/ml penicillin,
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123100 lg/ml streptomycin, 1% sodium pyruvate and 1% non-
essential amino acids.
Drugs
Erucylphosphohomocholine (ErPC3, Erufosine
TM) was
generously provided by Genzyme Pharmaceuticals (Lies-
tal, Switzerland). Antimycin A, butylated hydroxyanisole
(BHA), carbonyl cyanide 3-chlorophenyl-hydrazone
(CCCP), cyclosporin A, myxothiazol, oligomycin, ouabain,
piceatannol, and rotenone were obtained from Sigma–
Aldrich (St. Louis, MO).
Assay material
WST-1 reagent, Cell Death Detection ELISA
PLUS Kit (Cell
Death Kit), and ATP Bioluminescence Assay Kit CLS II
were from Roche Applied Science (Mannheim, Germany).
Bicinchoninic acid (BCA) protein assay reagents kit was
from Pierce (Rockford, IL, USA). The ﬂuorescent dye
5,50,6,60-tetrachloro-1,10,3,30-tetraethylbenzimidazolylcarbo-
cyanine iodide (JC-1) was from Calbiochem (Merck,
Darmstadt, Germany). Standard chemicals for the assays
described below were from various commercial sources.
Drug treatments
To induce apoptosis and collapse of the mitochondrial
membrane potential, human glioblastoma cells were treated
with ErPC3 as described previously [7–9, 12, 13]. The
involvementofROSgenerationinErPC3-inducedcelldeath
was studied by applying the ROS scavenger BHA as
described previously [34]. We measured ROS generation by
ErPC3 and its potential inhibition by BHA by assays of
cardiolipin oxidation, using 10-N-Nonyl-Acridine Orange
(NAO), according to methods applied previously [8, 18]. To
studytheinvolvementofthemitochondrialrespirationchain
intheseevents,wetreatedcellswiththefollowinginhibitors:
2 lM rotenone, 2 lg/ml antimycin A, 1 lM myxothiazol,
and5 lMCCCP.Theinhibitorconcentrationswereselected
according to procedures described previously [31, 37]. In
addition, we did viability tests and found that at these con-
centrations effects on viability did not appear to be a major
factor (see ‘‘Results’’; Fig. 4). An exception may be rote-
none, which showed moderate lethal effects at all concen-
trations higher than 50 nM applied to the U118MG cell line.
For these reasons, we decided to apply the concentrations
previously used by others [31, 37], to remain in line with
these studies. In the case of co-incubation with ErPC3, these
inhibitors were added to the culture medium 1 h prior to
ErPC3 treatment, for all experiments. The role of the mito-
chondrial FOF1-ATP(synth)ase in this system was assayed
by using the FOF1-ATP(synth)ase inhibitors oligomycin and
piceatannol,asdescribedbefore[13,31].Theconcentrations
ofoligomycin(5 lg/ml)andpiceatannol(5 lM)usedforthe
present study were effective as described in the ‘‘Results’’
and ‘‘Discussion’’. The drugs were dissolved in their
appropriate vehicles: DMSO (BHA, CCCP, rotenone), eth-
anol(antimycinA,cyclosporinA,oligomycin,piceatannol),
methanol(myxothiazol),ordoubledistilledwater(ouabain).
Measurement of cell viability
Cell viability was determined by the WST-1 assay
according to the manufacturer’s instructions as described
previously [7]. Brieﬂy, human glioblastoma cells were
seeded in ﬂat-bottom 96-well microtiter plates (1 9 10
4/
100 ll/well), allowed to attach overnight and treated with
different concentrations of respiration chain inhibitors and
uncoupler for 24 h. Control cells were treated with the
appropriate vehicles. WST-1 reactivity was measured with
an ELISA reader (TECAN, Zurich, Switzerland) at 450 nm
wavelength (reference 690 nm).
Apoptosis assays
Morphology
Morphological changes characteristic for apoptosis such as
rounding and membrane blebbing were documented by
phase-contrast microscopy with an inverted microscope
(Leica DM IRB, Leica Microsystems, Wetzlar, Germany).
DNA fragmentation
Cytoplasmic histone-associated DNA fragments indicating
ongoing apoptosis were quantitatively measured using the
Cell Death Kit, following manufacturer’s instructions, as
described previously [7]. ErPC3 was applied at the con-
centrations which are known to result in pronounced
apoptosis (U87MG: 45 lM; U118MG: 15 lM) [7, 8]. As
mentioned above, uncoupler and inhibitors of the mito-
chondrial respiratory chain and oxidative phosphorylation
were added to the culture medium 1 h prior to ErPC3
treatment. Apoptosis was assayed at the time points indi-
cated in the legends to Figs. 5, 6, and 8. Substrate
absorption indicative of apoptosis was measured at 405 nm
(reference 490 nm).
Caspase cleavage
U87MG and U118MG cells seeded in culture ﬂasks
(75 cm
2) were co-treated for 12 h with oligomycin or
piceatannol and ErPC3 (45 lM for U87MG, and 15 lM for
U118MG). Control cells were treated with vehicle only.
Following treatment, cells were harvested, washed,
Apoptosis (2010) 15:753–768 755
123transferred to microvials, and resuspended in 200 ll lysis
buffer (0.02% digitonin, 250 mM sucrose, 80 mM KCl,
5 mM EDTA). After 5 min on ice, cell lysates were cen-
trifuged (7009g, 10 min, 4C). Supernatants were trans-
ferred to fresh microvials and centrifuged for 25 min at
10,0009g,4 C, with the ﬁnal supernatants containing the
cytosolic fractions. The protein content of the cytosolic
fractions was quantiﬁed using bicinchoninic acid (BCA)
protein assay reagents, according to the manufacturer’s
instructions (Pierce). Equal protein amounts of the cyto-
solic fractions were used to detect caspase-3 processing by
SDS–PAGE and Western blot analysis with polyclonal
rabbit anti-cleaved caspase-3 (1:2000, Cell Signaling,
Beverly, MA) [7]. Labeling with COX IV (monoclonal
mouse anti-COX-IV, 1:2000, Molecular Probes, Eugene,
OR) was used as quality control for cell fractionation.
Membrane-bound antibodies were visualized using Im-
mobilon Western detection reagents (Millipore, Billerica,
MA). Loading and transfer of even amounts of protein was
conﬁrmed by Ponceau S staining.
Mitochondrial membrane potential assay
Collapse of the mitochondrial membrane potential (DWm)
was analyzed by ﬂuorescence assisted cell sorting (FACS)
using the ﬂuorescent lipophilic dye JC-1 as previously
described [7, 18, 38, 39]. Cells were seeded in 6-well plates
(2 9 10
5 cells/well). After achieving conﬂuence, culture
medium was changed to culture medium with or without
drugs (ErPC3, BHA, CsA, oligomycin, piceatannol) as
indicated in the ‘‘Results’’. Cells treated with drug vehicle,
are referred to as ‘‘control’’. As positive control for mito-
chondrial membrane potential depolarization we treated the
cells with the proton ionophor CCCP (50 lM). After drug
treatment, spontaneous free ﬂoating and trypsinized cells
were collected for DWm determination by ﬂow cytometry
using JC-1 dye according to the manufacturer’s instructions
(Calbiochem). Brieﬂy, cell suspensions were centrifuged at
5009g and the cell pellets were resuspended in 500 llo f
phosphate-buffered saline (PBS) at 4C and transferred to
FACS tubes (Falcon, Bedford, MA). Subsequently, 10,000
events were recorded per sample with a FACScan ﬂow
cytometer (Becton–Dickinson, Franklin Lakes, NJ) and
analyzed using CellQuest software (Becton–Dickinson,
Franklin Lakes, NJ).
ATP determination
Cellular ATP concentrations were determined based
on the luciferin-luciferase reaction using the ATP Biolu-
minescence Assay Kit CLS II (Roche Applied Science),
according to procedures described previously [40]. U87MG
and U118MG cells seeded in culture ﬂasks (25 cm
2) were
co-treated with oligomycin or piceatannol and ErPC3
(45 lM for U87MG; 15 lM for U118MG) for 12 h. Cells
were trypsinized and counted using Trypan blue solution to
calculate the amount of living cells. 1 9 10
5 living cells
were transferred to microvials, centrifuged at 8009g for
7 min at 4C, and the supernatant removed carefully. The
cell pellet was resuspended in 1 ml deionized water and
ATP was extracted by boiling for 10 min and subsequent
centrifugation at 12,0009g for 5 min at 4C[ 40]. The
resulting supernatant was used for bioluminescence mea-
surement of ATP levels according to the instructions pro-
vided by the manufacturer (Roche Applied Science).
Brieﬂy, 50 ll supernatant was mixed with 50 ll luciferase
reagent in triplicate in a white microtiter plate (clear bot-
tom) on a microplate luminometer (GloMax
TM 96, Pro-
mega, Madison, WI). The light signal was integrated for
10 s after a delay of 1 s. Using this assay, luminescence
(relative light units, RLU) is directly proportional to the
ATP concentration. Data of ATP levels were normalized as
a percentage of the value of the corresponding untreated
cells.
Data analysis
Data are expressed as means ± SD, n[5 (or n = 4i n
Fig. 3). To determine statistically signiﬁcant differences,
Kruskal–Wallis non-parametric, one-way analysis of vari-
ance (ANOVA) was carried out, since standard deviations
typically differed signiﬁcantly between groups, as indi-
cated by Bartlett’s test for homogeneity of variance. As the
sample sizes were relatively small, Mann–Whitney was
used as a post-hoc test, and P\0.05 was considered to
indicate statistically signiﬁcant differences. The program
used for statistical analysis was InstatGraphPad
TM
(GraphPad Software, San Diego, CA).
Results
The ROS scavenger butylated hydroxyanisole
and the MPTP inhibitor cyclosporin A inhibit
ErPC3-induced dissipation of DWm
Previously we had found that ErPC3 treatment activates the
TSPO, causing ROS generation at mitochondrial levels as
well as collapse of the DWm, indicative of MPTP opening,
and mitochondrial apoptosis pathway induction [7, 8]. In
the present study we wanted to determine whether ROS
generation by ErPC3 may actually contribute to MPTP
opening. To this end, the non-speciﬁc ROS scavenger
3-tert-butyl-4-hydroxyanisole (BHA; 200 lM) [34] was
applied prior to treatment with ErPC3 to counteract ROS
generation and the subsequent effects on DWm collapse.
756 Apoptosis (2010) 15:753–768
123Furthermore, the DWm was measured in U87MG and
U118MG cells that were treated with ErPC3 in the pres-
ence of the speciﬁc MPTP inhibitor cyclosporin A (CsA;
10 lM). Cyclosporin A is reported to inhibit the VDAC
component of the MPTP [41]. ErPC3 treatment consis-
tently caused robust and very signiﬁcant dissipation of
DWm in U87MG and U118MG glioblastoma cells, in
comparison to untreated controls (Fig. 1), as described
previously [7, 8]. This dissipation of DWm by ErPC3
treatment was prevented by co-treatment with BHA of
U87MG as well as U118MG cells i.e. BHA signiﬁcantly
reduced the number of cells undergoing DWm collapse
otherwise induced by ErPC3. In particular, both U118MG
and U87MG cells treated with BHA plus ErPC3 showed 5
times less cells displaying collapse of the DWm than cells
treated with ErPC3 only (Fig. 2). We also found that
ErPC3 induced cardiolipin oxidation, indicative of ROS
generation at mitochondrial levels (Fig. 3). The ROS
scavenger BHA, as expected, prevented ROS generation by
ErPC3 (Fig. 3). We also have found that BHA prevented
induction of apoptosis via the mitochondrial apoptosis
pathway [34], as also demonstrated previously by others in
different cell lines [42, 43]. Moreover, co-treatment of cells
with ErPC3 and the VDAC inhibitor CsA also signiﬁcantly
reduced the number of cells displaying collapse of DWm
compared to treatment with ErPC3 alone (in U87MG to
less than half; in U118MG to less than one-third; Fig. 2).
Consistent with previous studies, this indicates that ROS
generation by ErPC3 is required to cause opening of the
MPTP and in particular the VDAC component [8, 18, 44].
Depending on the cell line investigated, BHA and CsA
alone appear to have either no effect on DWm or slightly
depolarizing effects in U87MG and U118MG cells
(Fig. 2). Previously, as published as an abstract [34], we
had also assayed several traditional ROS scavengers to
establish the mechanism of ROS generation involved (in
addition to BHA described above). These data were at best
equivocal (see ‘‘Discussion’’), suggesting that ROS gen-
eration due to ErPC3, other than causing cardiolipin oxi-
dation at mitochondrial levels [8, and the present study],
does not play a major role in apoptosis induction by ErPC3
[34]. Thus, our present data indicate that BHA in our
experiment prevents ROS generation at mitochondrial
levels together with collapse of the Dwm and induction of
apoptosis that otherwise are caused by ErPC3 and TSPO
activation [8, 18].
Effects of inhibitors of respiration and uncouplers
on ErPC3-induced apoptosis
As we elucidated in the previous section that ErPC3-
induced ROS generation leads to MPTP opening and
apoptosis, we wanted to further investigate whether the
mitochondrial respiration chain is involved in these pro-
cesses induced by ErPC3. It has been suggested before that
the mitochondrial respiration chain may be involved in
ROS generation by ErPC3 and the TSPO [44–47]. We
chose the following uncoupler and inhibitors of various
aspects of the mitochondrial respiration chain system:
antimycin A, an inhibitor acting on center Qi of mito-
chondrial complex III and having the highest afﬁnity for
the bc1 complex; CCCP, one of the most frequently used
uncouplers of oxidative phosphorylation; myxothiazol, the
most tightly binding and potent inhibitor of complex III,
which also inhibits complex I; oligomycin, the classical
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Fig. 1 Effects of ErPC3 on the mitochondrial membrane potential
(DWm) in the glioblastoma cell lines U87MG using the dye JC-1. The
FACS patterns of U87MG cells labeled with JC-1 in the absence (a)o r
presence of ErPC3 (b) are shown. a Cells with polarized mitochondria
are found in the upper right quadrant of the plots, corresponding to
high emission of ﬂuorescence at both 590 nm (FL2-H, orange-red)
and 527 nm (FL1-H, green). b After ErPC3 treatment for 6 h
(U87MG), membrane depolarization becomes evident as a decrease
in the 590 nm signal and an increase in the 527 nm signal, in the lower
right quadrant. Lines deﬁning quadrants were arbitrarily chosen to
highlight changes in the ﬂuorescence of cell populations. On the
y-axis, red ﬂuorescence (emissions at 590 nm) indicates the mito-
chondrial uptake of the JC-1 dye and the formation of J-aggregates
within the matrix. On the x-axis, green ﬂuorescence (emissions at
527 nm) indicates cytosolic retention of the JC-1 monomers
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123inhibitor of mitochondrial FOF1-ATP(synth)ase; and rote-
none, the classic inhibitor of complex I of the respiratory
chain [48]. For our study, we applied concentrations of
these uncouplers and inhibitors as reported in previous
studies [31, 37]. We also used the WST-1 test to determine
viability of the cell lines U87MG and U118MG after
treatments with increasing concentrations of the different
inhibitors of the mitochondrial respiration chain (ranging
from 0.5 till 10 lM, or from 0.5 till 10 lg/ml) for 24 h
(Fig. 4). The WST-1 tests indicated that antimycin A did
not have any effects on cell viability in both glioma cell
lines and the same holds true for myxothiazol. Oligomycin
reduced cell viability of U118MG cells in a dose-depen-
dent manner, but not of U87MG cells. In this latter cell
line, rotenone exhibited a slight dose-dependent toxic
effect. In U118MG cells, rotenone displayed moderate
toxic effects at the same concentrations, as presented in
Fig. 4. With an additional assay, applying concentrations
lower than 0.5 lM, we found that 10–50 nM of rotenone
was virtually non-toxic for U118MG cells (data not
shown). CCCP also dose-dependently reduced survival of
both glioma cell lines as compared to untreated controls
(Fig. 4). With these assays, we also observed differences in
the basal absorbance entity between U87MG and U118MG
cells obtained. This could indicate a difference in either the
amount of viable cells (due to differences in proliferation)
or in the mitochondrial metabolic activity (e.g. due to
reduced number of mitochondria or modiﬁed mitochondria
[49]). Furthermore these data show that in terms of cell
death induction, U118MG is more sensitive to inhibitors
and uncouplers of the mitochondrial respiration chain than
U87MG, in particular regarding uncoupling of oxidative
phosphorylation and inhibition of mitochondrial FOF1-
ATP(synth)ase. Additionally, it was noticed that the via-
bility values presented in Fig. 4 show both positive and
negative changes for different substances, but this aspect
was not investigated further as it was not part of the present
project. Thus, in accord with previous studies [31, 37], our
data indicate that the following concentrations of the
respiratory chain inhibitors and uncouplers (2 lM rote-
none, 2 lg/ml antimycin A, 1 lM myxothiazol, 5 lM
CCCP, and 5 lg/ml oligomycin) are appropriate to study
their effects of co-administration with ErPC3.
Using the Cell Death Kit we could show in a quantita-
tive manner that most of the inhibitors and uncouplers of
the mitochondrial respiration chain tested did not inﬂuence
Fig. 2 Effects of BHA and CsA on ErPC3-induced breakdown of the
inner mitochondrial membrane potential (DWm) in the glioblastoma
cell lines U87MG and U118MG using the dye JC-1. U87MG (a) and
U118MG (b) cells were treated with ErPC3 (45 and 15 lM,
respectively) and/or BHA (200 lM) or CsA (10 lM) for 6 h
(U87MG) and 8 h (U118MG) and DWm was evaluated as illustrated
in this ﬁgure and in Fig. 1. The percentages displayed in each column
refer to the cell numbers in the lower right quadrant of the DWm
analysis plot as a fraction of the total numbers of cells analyzed
(example displayed in Fig. 1). These average percentages are derived
from each time 9 independent experiments. In both cell lines
co-treatment with BHA or CsA reduced the incidence of DWm
collapse otherwise induced by ErPC3 itself. *** P\0.001 versus the
appropriate control; ** P\0.01 versus the appropriate control;
### P\0.001 versus ErPC3;
 P\0.01 versus CsA;
 P\0.001
versus CsA
Fig. 3 Effects of BHA on ErPC3-induced cardiolipin oxidation,
indicative of mitochondrial ROS generation, as determined with 10-
N-Nonyl-Acridine Orange (NAO) by FACS. U118MG glioblastoma
cells were treated with ErPC3 (7.5 lM) and/or BHA (200 lM) for
24 h. Control was treated with vehicle. The level of measured
cardiolipin oxidation in the control is referred to as 1. The levels of
cardiolipin oxidation in the experimental groups (BHA; ErPC3;
(ErPC3) ? BHA) are represented as relative to the control. These
averages are derived from each time 4 independent experiments.
ErPC3 enhanced cardiolipin oxidation. Addition of BHA to ErPC3
treatment reduced NAO labelling to control levels. BHA by itself
reduced NAO labelling to below control levels. * P\0.05 versus
control;
# P\0.05 versus ErPC3
758 Apoptosis (2010) 15:753–768
123ErPC3-induced apoptosis in U87MG and U118MG cells.
An exception was oligomycin (5 lg/ml), which is a spe-
ciﬁc inhibitor of the membranous proton channel (FO)o f
mitochondrial FOF1-ATP(synth)ase and consequently an
inhibitor of oxidative phosphorylation and of the mito-
chondrial electron transport chain [27–32, 50]. This
inhibitor of complex V was found to robustly and signiﬁ-
cantly reduce apoptotic levels induced by ErPC3 in
U87MG and U118MG cells. Compared to treatment of
U87MG cells with ErPC3 alone, co-treatment of U87MG
cells with oligomycin caused signiﬁcant reductions by 58%
of apoptotic levels otherwise induced by ErPC3 (Fig. 5a).
Also co-treatment of U118MG with this drug caused very
signiﬁcant reductions by 87% of apoptotic levels otherwise
induced by ErPC3 (Fig. 5a).
For our study, we took into consideration that in mam-
malian cells oligomycin can be highly toxic [48]. In par-
ticular, depending on the cell line used, treatment with
oligomycin can induce cell death after 12–13 h. Therefore,
in all experiments oligomycin by itself was applied during
1 h before treatment and subsequently in combination with
ErPC3 for 12 h in all experiments. Subsequent experiments
were performed within the ﬁrst 12 h after ErPC3 treatment
and we conﬁrmed that oligomycin did not cause cell death
during this time period ([95% trypan blue dye exclusion in
control cultures). As mentioned above, inhibitors of res-
piration and uncouplers per se typically did not promote
the induction of apoptosis in both cell lines even after 24 h
of treatment (Fig. 5b). Thus our data suggest that in par-
ticular the FO subunit of the ATP(synth)ase is important for
apoptosis induction by ErPC3.
At higher concentrations [IC50 2.2 lM] oligomycin has
also been reported to interfere with a non-mitochondrial
target, the plasma membrane Na
?/K
? ATPase [51]. We
therefore tested the effect of ouabain, a speciﬁc Na
?/K
?
ATPaseinhibitor[52],inbothgliomacelllines.Thereported
IC50 for ouabain is 50 nM in vascular smooth muscle sar-
colemma [53]. To ensure the effectivity of ouabain in our
models, we selected the relatively high concentration of
100 nM of ouabain. This concentration of ouabain moder-
ately affected viability of both the U118MG and U87MG
cells (data not shown). Higher concentrations could be toxic
in our models. Thus, ours and studies of others showed that
ouabain is active at 100 nM. We found that, in contrast to
oligomycin, ouabain did not suppress ErPC3-induced
apoptosis (Fig. 5a). These results suggest that down-
Fig. 4 Effects of mitochondrial
inhibitors on viability of human
glioma cell lines. Viability of
U87MG (a) and U118MG (b)
cells was measured by the
WST-1 test after incubation for
24 h with increasing
concentrations of the following
mitochondrial inhibitors:
antimycin A, myxothiazol,
oligomycin, rotenone, and
CCCP, as indicated on the
x-axes. Cells treated with
vehicle only served as control
(-). Absorption of 450 nm
(A450nm) was used as a positive
measure for cell viability. For
U87MG n = 12; for U118MG
n = 6. * P\0.05 versus
control (-); ** P\0.01 versus
control (-); *** P\0.001
versus control (-)
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123regulation of ErPC3-mediated apoptosis by oligomycin is
not related to Na
?/K
? ATPase suppression. These results
further support our conclusion that the mitochondrial FOF1-
ATP(synth)ase is required for ErPC3-induced apoptosis.
It has been reported that cell death triggered by oligo-
mycin can be delayed by culturing cells in high glucose-
containing medium, which helps to maintain ATP levels via
glycolysis [54]. We routinely cultured the U87MG and
U118MG glioma cells in media containing 6 mmol/l glu-
cose, which is close to reported physiological levels
(5 mmol/l),suggestingthatourconditionswouldnotcausea
delay of cell death potentially triggered by oligomycin.
Nonetheless,wewantedtoanswerthequestionwhethersuch
a confounding temporalelement isinvolved in the reduction
of ErPC3-induced apoptosis by oligomycin. Therefore, we
assessed cytoplasmic histone-associated DNA fragments
indicative of ongoing apoptosis in U118MG cells after 3, 6,
12, and 24 h of co-treatment with oligomycin (Fig. 6).
Withinthetimeframeoftheexperiment5 lg/mloligomycin
by itself did not affect apoptosis levels under all conditions
tested (Fig. 6). Furthermore, at all time points after appli-
cation (6, 12, and 24 h) oligomycin robustly reduced apop-
tosis levels induced by ErPC3 (by 90, 91, and 76%,
respectively). This indicates that the results obtained were
not adversely affected by time-dependent effects of oligo-
mycin on modulation of apoptosis induction. Apart from the
measured DNA fragmentation, effects of ErPC3 and oligo-
mycin on apoptosis were also studied microscopically.
Compared to untreated cells (Fig. 7a), ErPC3 by itself
caused apoptotic morphological changes such as rounding
and blebbing of our human glioblastoma cells (Fig. 7d),
while oligomycin showed no effects by itself (Fig. 7b).
Co-treatment of ErPC3 with oligomycin reduced the apop-
totic effects of ErPC3 (Fig. 7e).
Effect of the F1-ATP(synth)ase inhibitor piceatannol
on ErPC3-induced apoptosis
To assess in more detail the potentially speciﬁc role of the
mitochondrial FOF1-ATP(synth)ase in the execution of
ErPC3-induced cell death, we tested piceatannol, another
speciﬁc inhibitor of this mitochondrial enzyme. In contrast
to oligomycin, which targets the membrane (lipid phase)-
directed FO, piceatannol targets speciﬁcally the matrix
Fig. 5 Effects of inhibitors of respiration and uncouplers on ErPC3-
induced apoptosis. a U87MG and U118MG cells were co-incubated
with ErPC3 plus different respiratory chain inhibitors and uncouplers
for 12 h and apoptotic levels were determined using the Cell Death
kit. Cells treated with ErPC3 alone or not treated at all were used as
controls. ErPC3 induced apoptosis in both cell lines, and oligomycin
reduced this signiﬁcantly in both cell lines. The other respiratory
inhibitors and uncouplers did not counteract apoptosis induction by
ErPC3. b In the U87MG cell line, rotenone and ouabain by
themselves could induce apoptosis. Otherwise, the respiratory inhib-
itors and uncouplers per se typically did not promote the induction of
apoptosis in the two cell lines. Absorbance of the 405 nm wavelength
is indicative for the level of apoptosis. The results are the
means ± SD (n = 6). ** P\0.01 versus the appropriate control;
## P\0.001 versus the appropriate ErPC3
Fig. 6 Time course of ErPC3-induced apoptosis, with and without
co-treatment with oligomycin. Apoptotic rates were followed by
assessment of cytoplasmic histone-associated DNA fragments using
the Cell Death Kit at various times after ErPC3 plus oligomycin
co-treatment of U118MG cells. Open bars, vehicle-treated cells; grey
bars,5 lg/ml oligomycin (OL); closed bars,1 5 lM ErPC3; and
hatched bars, oligomycin ? ErPC3 (OL/Er3). Absorbance of the
405 nm wavelength is indicative for the level of apoptosis. The results
shown are the means ± SD. (n = 6) ** P\0.01 versus control of
the same time period;
## P\0.01 versus ErPC3 of the same time
period;
 P\0.05 versus ErPC3 of 3 h;
 P\0.01 versus ErPC3 of
3h ;
 P\0.01 versus Ol/Er3 of 3 h
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123(water phase)-exposed catalytic F1 component of the
enzyme [55] and therefore inhibits the ATP(synth)ase by a
different mechanism from that of oligomycin. We selected
a concentration of 5 lM, which is slightly above the IC50
(4 lM) of piceatannol on ATPase activity of the puriﬁed
F1 complex [55]. We found that 5 lM of piceatannol was
effective in decreasing ATP levels in both cell lines (see
further below for details). With pilot studies we had found
that concentrations of piceatannol lower than 20 lM
(including the 5 lM concentration used for the present
study) did not affect the viability of both cell lines (data not
shown). Furthermore, in contrast to oligomycin, 5 lM
piceatannol was not able to reduce apoptosis levels other-
wise induced by ErPC3 (Figs. 7c, f, 8).
Effects of FOF1-ATP(synth)ase inhibition on
dissipation of the DWm and caspase activation as
components of the mitochondrial apoptosis pathway
typically activated by ErPC3
As described previously [35], treatment of U87MG and
U118MG cells with ErPC3 caused manifold increases in
the number of cells displaying collapse of the DWm in
comparison to untreated cells (Fig. 9). Compared to treat-
ment of U87MG cells with ErPC3 alone, co-treatment of
U87MG cells with oligomycin caused signiﬁcant reduc-
tions by 80% of the number of cells undergoing collapse of
DWm (Fig. 9b). Also co-treatment of U118MG with this
inhibitor caused signiﬁcant reductions by 91% of the
number of cells displaying collapse of DWm, otherwise
induced by ErPC3 (Fig. 9c). Oligomycin alone, at a con-
centration of 5 lg/ml, did not appear to have an effect on
DWm in U87MG and U118MG cell lines (Fig. 9b, c).
Piceatannol, however, does not modulate collapse of DWm,
neither alone nor in combination with ErPC3 (Fig. 9b, c).
As another parameter of apoptosis induction, caspase-3
cleavage in response to ErPC3 was abrogated in the pres-
ence of oligomycin but not piceatannol (Fig. 10).
Fig. 7 U118MG cells were treated for 12 h with ErPC3, with or
without oligomycin or with or without piceatannol, and apoptotic
morphological changes such as rounding and blebbing were observed
by phase-contrast microscopy. Code for the micrographs: a untreated;
b oligomycin; c piceatannol; d ErPC3; e ErPC3 ? oligomycin;
f ErPC3 ? piceatannol. Compared to untreated cells (a), ErPC3 by
itself caused apoptotic morphological changes (d), while oligomycin
and piceatannol showed no effects by themselves (b, c). Co-treatment
of ErPC3 with oligomycin reduced the apoptotic effects of ErPC3 (e),
whereas co-treatment with piceatannol had no effect (f). Together,
these results suggest that the activity of the F0F1-ATP(synth)ase,
speciﬁcally the F0 component, is essential for ErPC3-induced
apoptosis
Fig. 8 Co-treatments with piceatannol showed no effect on ErPC3-
mediated apoptosis as assayed with the Cell Death Kit. U87MG and
U118MG cells were incubated for 12 h with piceatannol (Pic) or with
ErPC3, or with ErPC3 in combination with Pic, or treated with
vehicle (control). Absorbance of the 405 nm wavelength is indicative
for the level of apoptosis. (n = 4) * P\0.05 versus control
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123Effect of oligomycin and piceatannol on ErPC3-
induced decrease of intracellular ATP levels
As oligomycin inhibits ATP production by oxidative
phosphorylation, which may play a role in the apoptotic
process, we investigated changes of intracellular ATP
levels during ErPC3 treatment in the presence of
oligomycin or piceatannol. The luciferin/luciferase-based
detection procedure used revealed on the one hand an
increase of intracellular ATP levels by 28% in U87MG
cells and, on the other hand, a reduction by 31% in
U118MG cells upon treatment with oligomycin alone
(Fig. 11a). Treatment with piceatannol alone caused
decreases of intracellular ATP levels in U87MG cells as
well as in U118MG cells, by 37% and 16%, respectively,
compared to untreated control cells (Fig. 11b). In parallel
to its pro-apoptotic effects, ErPC3 caused robust and sig-
niﬁcant reductions in ATP levels in both cell lines
(Fig. 11). Co-incubation with oligomycin rescued from the
ErPC3-induced decrease in intracellular ATP levels by a
factor of 3 for U87MG cells and a factor of 6 for U118MG
cells (Fig. 11a). Indeed, in U87MG cells, co-incubation of
ErPC3 with oligomycin even restored ATP levels to con-
trol levels (Fig. 11a). In U87MG cells, co-incubation with
piceatannol provided modest protection against ErPC3
induced ATP depletion (from a 6 fold reduction to a 4.5
fold reduction; Fig. 11b). In U118MG cells piceatannol
was ineffective in this respect (Fig. 11b).
These results regarding restoration of ATP levels
otherwise depleted by ErPC3 parallel the speciﬁc capacity
of oligomycin to block ErPC3-induced apoptosis. Consis-
tently, as piceatannol did not protect against apoptosis
induced by ErPC3 in both cell lines, it did not effectively
counteract ATP depletions due to ErPC3 treatment either.
Discussion
It is well known that loss of the DWm can lead to the release
of apoptogenic factors, e.g. cytochrome c, apoptosis-
inducing factor (AIF), and Smac/Diablo from the mito-
chondrial intermembrane space [56]. When the MPTP
opens, the DWm collapses as a consequence of the dissi-
pation of the proton gradient generated in the mitochon-
drial intermembrane space. In addition, it has been
suggested that opening of the MPTP uncouples the respi-
ratory chain and can lead to overproduction of superoxide
anions [56]. In previous studies we have shown that ErPC3,
as well as various other agents, requires TSPO to induce
apoptosis. TSPO is a protein in the outer mitochondrial
membrane that is associated closely with the MPTP, and
appears to be involved in apoptosis [15, 16, 18, 57]. In
particular, knockdown of the TSPO by genetic manipula-
tion, as well as application of TSPO inhibitors, was found
to prevent opening of the MPTP, generation of ROS at
mitochondrial levels, including cardiolipin oxidation, and
subsequent cell death, including activation of the mito-
chondrial apoptosis pathway [7, 8, 17, 18, 38, 45]. These
studies also showed that ErPC3 can induce ROS generation
via the TSPO. Our present study is consistent with this
Fig. 9 Effects of ErPC3, oligomycin and piceatannol on the inner
mitochondrial membrane potential (DWm) in the glioblastoma cell
lines U87MG and U118MG using the dye JC-1. In a, the inﬂuence on
the DWm of ErPC3 treatment of U87MG and U118MG cells after
various time periods is shown. For clarity, error bars are shown either
above or below the lines. In b, c the effects of ErPC3, oligomycin and
piceatannol on DWm are shown. U87MG (b) and U118MG (c) cells
were treated with ErPC3 (45, 15 lM, respectively) and/or oligomycin
or piceatannol for 6 h (U87MG) and 8 h (U118MG). Each column
represents the mean values of cell percentages derived from each time
9 independent experiments in the LR quadrant of the DWm analysis
plot (depolarized mitochondria). In both cell lines co-treatment with
oligomycin reduced the incidence of DWm collapse otherwise induced
by ErPC3 itself, while piceatannol had no such effect. *** P\0.001
versus control.
### P\0.001 versus ErPC3
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123observation, as application of the ROS scavenger BHA
prevents ROS generation as well as DWm collapse and
apoptosis otherwise induced by ErPC3. Thus, our ﬁndings
strongly support the notion that ROS generation constitutes
a signal required for the execution of apoptosis in U87MG
and U118MG glioblastoma cells upon activation of the
TSPO by ErPC3.
We also assayed ROS generation other than indicated by
cardiolipin oxidation after ErPC3 application [34]. The
results were at best equivocal. In particular, iron chelators
(deferoxamine, phenanthroline) could occasionally block
apoptosis induced by ErPC3 in U373MG glioblastoma
cells, but never in A172 glioblastoma cells. Sulfhydryl
reagents (dithiotreitol, glutathione), superoxide dismutase,
N-acetylcysteine, vitamin E (a-tocopherol) and its water-
soluble derivative, Trolox, did not have any effect on
ErPC3-induced cell death. Catalase occasionally inhibited
ErPC3-mediated apoptosis in A172 cells, but never in
U373MG cells [34 and unpublished data]. The present data
combined with previous studies [8, 18, 44] suggest that
ROS generation by ErPC3 may be a rather speciﬁc process
taking place at the mitochondrial level, including cardio-
lipin oxidation.
One question emerging from these studies was by which
mechanism TSPO activation by ErPC3 can lead to mito-
chondrial ROS generation. It has been implicated that
TSPO by itself, via interactions with its ligands, may be
able to generate electrons that subsequently may participate
in the generation of ROS [8, 44]. Furthermore, TSPO is
known to interact with O2 [58], which may present a fur-
ther contribution to ROS generation. Another suggestion
was that the reported activation of the mitochondrial res-
piration chain by TSPO could also participate in ROS
generation and subsequent induction of apoptosis [44–46,
59–61]. To study whether the mitochondrial respiratory
chain could affect MPTP opening and the induction of the
mitochondrial apoptosis cascade by ErPC3 in human
glioblastoma cells, we applied the following mitochondrial
respiration chain inhibitors and uncouplers: antimycin A
(complex III inhibitor), myxothiazol (complex III and I
Fig. 10 Western blot protein analysis of effects of oligomycin (OL)
and piceatannol (Pic) on ErPC3-induced caspase-3 processing.
U87MG and U118MG cells were incubated for 12 h with ErPC3
alone, or in combination with either oligomycin or piceatannol, or
treated with vehicle only (control). Co-treatment with oligomycin
blocked the effects of ErPC3 on caspase-3 processing, whereas
piceatannol did not. COX IV was used as quality control for the purity
of the cytoplasmic fractions. Co
? denotes glioma whole cell lysate
used as a positive control for COX IV
Fig. 11 Effects of F0F1-ATP(synth)ase inhibitors on ErPC3-induced
decrease in cellular ATP levels. U87MG and U118MG cells were
treated for 12 h with oligomycin (a, n = 9), or piceatannol
(b, n = 6), or ErPC3, or ErPC3 in combination with either
oligomycin or piceatannol (OL/Er3, Pic/Er3), or left untreated
(control). Cellular ATP levels were determined by bioluminescence
measurement and the data were normalized as a percentage of the
value of the corresponding untreated cells. *** P\0.001 versus
control; ** P\0.01 versus control;
### P\0.001 versus ErPC3;
## P\0.01 versus ErPC3
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123inhibitor), rotenone (complex I inhibitor), and CCCP
(uncoupler of oxidative phosphorylation) [48]. These
compounds did not affect ErPC3’s typical induction of
Dwm collapse i.e. opening of the MPTP, and subsequent
activation of the mitochondrial apoptosis pathway. As the
mitochondrial respiration chain inhibitors and uncouplers
do not mimic the pro-apoptotic effect of ErPC3 in U87MG
and U118MG cells in our study, and neither do inhibit the
pro-apoptotic effects of ErPC3, it appears that the mito-
chondrial respiration chain does not play a major role in
apoptosis induction by ErPC3. This further suggests that
these components of the mitochondrial respiration chain do
not participate in ROS generation by ErPC3, i.e. TSPO
activation, in human glioblastoma cells. This is in accord
with other studies that have shown that respiration is not
required during apoptosis in yeast and in some mammalian
cells [30, 62]. Interestingly, studies have suggested that
some components of the mitochondrial respiration chain
may malfunction in brain tumors [63], giving further cre-
dence to our postulation that ErPC3 does not require
complex I–IV of the mitochondrial respiration chain to
induce apoptosis.
In contrast to the non-effects of the inhibitors of the
respiration chain discussed above, the application to the
U118MG and U87MG cell lines of oligomycin, the clas-
sical inhibitor of mitochondrial FOF1-ATP(synth)ase
(complex V), prevented not only collapse of DWm, but also
the activation of caspase-3 and DNA fragmentation
induced by ErPC3, as well as the morphological appear-
ance of apoptotic cells. Thus, the mitochondrial FOF1-
ATP(synth)ase appears to be important for apoptosis
induction by ErPC3 i.e. activated TSPO. Previously, Cleary
et al. [64] demonstrated that the classical TSPO ligand
PK11195 inhibits FOF1-ATP(synth)ase activity in an oli-
gomycin sensitivity conferring protein (OSCP)-dependent
manner. To further investigate which one of the FO and F1
subunits of ATP(synth)ase may be more important in this
respect, we compared the effects of oligomycin, an FO
inhibitor, with piceatannol, an F1 inhibitor. While oligo-
mycin consistently inhibited all apoptotic effects induced
by ErPC3, piceatannol did not. Thus, our data show con-
vincingly that piceatannol does not have an effect on
ErPC3 function i.e. F1 does not appear to affect ErPC3
function. This indicates that the FO component of the FOF1-
ATP(synth)ase is required for the pro-apoptotic effects of
ErPC3 in these human glioblastoma cells, while the F1
subunit is not. It is well known that piceatannol application
does not only affect the F1 of ATP(synth)ase, but also other
systems at the concentration we used for the present study,
and even more so at higher concentrations [65, 66].
Therefore we did not apply higher concentrations of
piceatannol to avoid complications of the interpretations of
the results. As piceatannol did not modulate pro-apoptotic
effects of ErPC3 at the concentration we used, our results
also indicate that these other systems are also not involved
in ErPC3-induced apoptosis. This latter observation is
however not the subject of our study. Recently it was found
that the catalytic F1 subunit is downregulated in carcino-
mas from liver, kidney, colon, oesophagus, lung, breast and
stomach [33, 67]. It would be interesting to determine
whether the F1 function actually is hampered in the two
glioblastoma cell lines we used and, more generally, in
glioblastoma multiforme. It has been suggested by others
that in human glioblastoma both F1 and FO expression may
be affected [68, 69]. As our and other studies show that the
FOF1-ATP(synth)ase function may have tumorigenic
implications, more studies on F1 and FO expression and
functions in human glioblastoma could be beneﬁcial.
Interestingly, it has been suggested in isolated mitochon-
dria that the TSPO can affect the FOF1-ATP(synth)ase
function [70].
As our study indicates that the FO subunit of ATP
(synth)ase rather than the F1 subunit is needed for apoptosis
induction by ErPC3, our data also suggest that the effect of
ErPC3 on ROS generation is due to its effects on the FO
proton pump. Two possibilities can be considered whereby
ErPC3 treatment leads to generation of mitochondrial ROS
via an effect on the FO proton pump. Mitochondrial ROS
can be generated in the intermembrane space as well as the
matrix [47]. At present it is not clear whether ErPC3
induces ROS generation in the matrix or intermembrane
space. It, for example, has been suggested that a high pH in
the matrix can cause ROS generation [71]. In such a sce-
nario the ErPC3 may act by stimulating the FO to pump
protons from the matrix to the intermembrane space,
thereby alkalizing the matrix and allowing for generation
of ROS. Alternatively, ErPC3 could cause protons to be
pumped to the matrix, alkalizing the intermembrane space
i.e. reverse the proton pump. In any case, oligomycin
would inhibit the effects of ErPC3 by suppressing FO
activity. Some of the protective effect of BHA may be due
to its ability to make the inner mitochondrial membrane
more permeable for protons [72], thus counteracting the
effects ErPC3 on the FO proton pump. More studies are
needed to exactly understand the mechanisms around FO in
relation to ErPC3 regarding ROS generation at mitochon-
drial levels.
While our data suggest that the FO proton pump of
ATP(synth)ase due to its potential effect on ROS genera-
tion is important for apoptosis induction by ErPC3, our
data further indicate that ATP depletion due to ErPC3
application may also play a role. Since ErPC3 depletes
ATP levels, and piceatannol actually does the same, this
may explain in part the lack of a protective effects by
piceatannol. In this context, the protective effects of oli-
gomycin against ATP depletion otherwise caused by
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123ErPC3 are somewhat surprising. However, it is known that
treatment with oligomycin can stimulate aerobic glycolysis
due to blockade of the FO subunit of the FOF1-ATP
(synth)ase [33]. Thus, the resulting increase in ATP levels
by this stimulation of aerobic glycolysis may compensate
for ATP depletion otherwise caused by a reduced function
of the FOF1-ATP(synth)ase. Another question relates to the
different effects of oligomycin by itself on ATP levels of
U118MG cells and U87MG cells, respectively a decrease
and an increase. We suggest that oligomycin can have
different effects on ATP levels in different cell lines,
depending on which metabolic pathway (glycolysis vs.
oxidative phosphorylation) is mainly active. Furthermore,
as inhibition of the mitochondrial respiration chain in the
present study does not appear to affect apoptosis induction
by ErPC3, the electron transport chain may also not be
essential for ATP depletion by ErPC3. This is in agreement
with studies reporting that q
o cells lacking a functional
electron transport chain still are able to generate ATP, as
well as to undergo apoptosis [24–26].
Regarding processes other than ROS generation and
ATP depletion leading to apoptosis, it was shown earlier
that oligomycin can inhibit opening of the MPTP [73].
Furthermore, oligomycin can also block Bax dimerization
[30, 74]. Indeed, intact FOF1-ATP(synth)ase is necessary
for optimal function of Bax [30, 74]. Bax is considered to
be required for cytochrome c release, which contributes to
the initiation of the mitochondrial apoptosis pathway [75,
76]. Furthermore, it was found previously that Bax is
necessary for ErPC3-induced apoptosis [77]. Bax is also
considered to be involved in TSPO-induced apoptosis [44].
In addition, using the Bax-negative prostate cancer cell line
DU145, we were able to demonstrate drastically reduced
apoptosis levels after ErPC3 treatment (unpublished
results). Preliminary data by us further suggest that oligo-
mycin may also reduce cytochrome c release otherwise
induced in U118MG cells exposed to ErPC3. Thus, Bax
and its related functions may also be important for apop-
tosis induction by ErPC3.
As a ﬁnal point, our and other studies indicate that ROS
generation at mitochondrial levels can lead to MPTP
opening, as mentioned above [17, 60]. On the other hand,
various studies have indicated that opening of the MPTP
can lead to ROS generation as well [78]. This suggests that
the effective apoptosis induction by ErPC3 via TSPO
activation and, consequently ROS generation that opens the
MPTP, may be due to a powerful reciprocal cycle of ROS
generation leading to MPTP opening and vice versa. Such
ROS-induced ROS release has also been described in other
systems [79, 80].
In summary, this study provides evidence that ROS
generation due to TSPO activation by ErPC3 may be
involved in opening of the MPTP leading to activation of
the mitochondrial apoptosis pathway. One component of
the mitochondrial respiratory chain, FOF1-ATP(synth)ase
may take part in this effect of ErPC3. In particular, the FO
component of the FOF1-ATP(synth)ase appears to be
important in this respect, suggesting that proton exchange
at mitochondrial levels takes part in the ROS generating
and apoptotic effects of ErPC3 and TSPO. Furthermore,
ATP depletion due to ErPC3 treatment may play a role in
the induction of apoptosis. The present study, applying
pharmacological means, may give directions to future
research, for example knockdown studies to reduce
expression of proteins involved in mitochondrial respira-
tion in relation to ROS generation and apoptosis induction
by ErPC3 and TSPO.
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